Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma: early-phase trial registry
89 of 269 indexed Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #36 of 28,707 conditions by registered trial count.
269 US clinical trials · 89 currently recruiting · #36 of 28,707 conditions by registered trial count
Melanoma: 269 US clinical trials tracked, 89 recruiting.
Melanoma is the subject of 269 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 184 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition melanoma
OPEN 89 | RECR 33% | LATE 19 | EARLY 184 | RANK #36 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Melanoma lists 89 open slots (33% of 269 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma is recruiting below its size-band peers.
89 of 269 indexed trials (33.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Melanoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 20 of 269 trials (7.4%). 139 distinct sponsors appear on at least one study for this condition label.
-
Typical Melanoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 267 trials that report a genuine target (sentinel values excluded). 155 of those (58.1%) plan for fewer than 100 participants.
-
Melanoma research is mostly interventional.
231 interventional and 38 observational studies make up this index (85.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
269 total, page 6 of 6
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Ohio State University Comprehensive Cancer Center
NCT01462773
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Cancer Institute (NCI)
NCT02107963
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
Craig L Slingluff, Jr
NCT00912418
Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer
Mayo Clinic
NCT05740501
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma
NCT00818480
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
Memorial Sloan Kettering Cancer Center
NCT01456104
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
NCT02451488
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
Bristol-Myers Squibb
NCT01245556
CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases
University of Pittsburgh
NCT02058953
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
NCT01894672
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
NCT03455764
Can We Miss Pigmented Lesions in Psoriasis Patients?
University of Alabama at Birmingham
NCT01053819
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
NCT03092453
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)
Duke University
NCT04570722
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Gradalis
NCT02574533
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Yale University
NCT01781026
Study of Talabostat and Cisplatin in Advanced Melanoma
Point Therapeutics
NCT00083252
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
GenVec
NCT00261404
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 117 |
| Phase 2 | 67 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma page
269 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Melanoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma condition card totals 269 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.